C/EBPJ3 in bone marrow stromal cell-mediated drug resistance of multiple myeloma
C/EBPJ3 in bone marrow stromal cell-mediated drug resistance of multiple myeloma
批准号:
10618417
负责人:
Gangqing Hu
金额:
$26.32万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-04-25 至 2023-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Epigenetic regulation plays a critical role in numerous biological processes. The overarching goal of my
laboratory is to understand epigenetic mechanisms of drug resistance of hematological cancers in the bone
marrow (BM) microenvironment. I have over 12 years of research experience on transcription regulation of
chromatin regulators in immune cells, embryonic stem cells, and cancer cells. This proposal is to investigate
the transcription-regulatory role of a leucine-zipper TF C/EBPβ in promoting de novo drug resistance of
Multiple Myeloma (MM) in the BM microenvironment. MM is a disease caused by malignant plasma B cells
mainly proliferating in the BM. It is incurable largely because of the emergence of drug resistance after
treatments. One important contribution to drug resistance stems from the protective effect of the BM
microenvironment, which includes growth promoting soluble factors and physical interaction with cellular
components such as stromal cells and osteoblasts. The emergence of de novo drug resistance occurs in a
short timeframe and is reversible, suggesting epigenetic mechanisms as an important contributor.
However, the identities and mechanisms of chromatin regulators contributing to de novo drug resistance of
MM in the BM microenvironment remain largely unexplored. Our preliminary results indicated C/EBPβ as a
key transcription regulator of target genes of signaling pathways activated by BM stromal cells. The BM
stromal cells induced a genome-wide reprogramming in gene expression (transcriptome) and chromatin
accessibility (regulome) of MM cells, turned out being mainly driven by soluble factors. Integrative analysis
with ENCODE genomic binding data indicated C/EBPβ as a major contributor to the BM stromal cellinduced
transformation of transcriptome and regulome. As C/EBPβ- overexpression protects MM cells from
IMiD compounds, our preliminary results defined C/EBPβ as a promising and new research subject to
understand epigenetic mechanisms for the emergence of de novo drug resistance in MM. We hypothesize
that C/EBPβ contributes to soluble factor-mediated drug resistance by transcriptionally regulating
target genes of growth-promoting signaling pathways activated by BM stromal cells through
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
C/EBPJ3 in bone marrow stromal cell-mediated drug resistance of multiple myeloma
-
批准号:10620611
-
项目类别:
-
资助金额:$26.37万
-
财政年份:2018
-
负责人:Gangqing Hu
-
依托单位:
C/EBPβ in bone marrow stromal cell-mediated drug resistance of multiple myeloma
-
批准号:10709274
-
项目类别:
-
资助金额:$23.78万
-
财政年份:2018
-
负责人:Gangqing Hu
-
依托单位:
国内基金
海外基金
登录
查看更多内容
骨病多模态报告和数据系统(Bone-RADS):规范精准风险评估并优化诊疗管理建议的临床研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:5.0万元
-
批准年份:2024
-
负责人:钟京谕
-
依托单位:
酶响应的中性粒细胞外泌体载药体系在眼眶骨缺损修复中的作用及机制研究
-
批准号:82371102
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:苏蕴
-
依托单位:
精氨酸调控骨髓Tregs稳态在脓毒症骨髓功能障碍中的作用研究
-
批准号:82371770
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:宁铂涛
-
依托单位:
慢性炎症诱发骨丢失的机制及外泌体靶向治疗策略研究
-
批准号:82370889
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:傅德皓
-
依托单位:
骨髓ISG+NAMPT+中性粒细胞介导抗磷脂综合征B细胞异常活化的机制研究
-
批准号:82371799
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:杨程德
-
依托单位:
槲皮素控释系统调控Mettl3/Per1修复氧化应激损伤促牙周炎骨再生及机制研究
-
批准号:82370921
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:徐袁瑾
-
依托单位:
基于AMPK/PGC-1α信号轴的工程化外泌体靶向调控BMSCs能量代谢重编程在老年机体骨修复中的作用及其机制研究
-
批准号:82370920
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:周名亮
-
依托单位:
MFB(Main Fractured Bone)概念结合AO分型对桡骨远端骨折的临床诊疗研究
-
批准号:2018JJ4093
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2018
-
负责人:许谭妙
-
依托单位:
Fgf19对耳蜗毛细胞发育调控机制的研究
-
批准号:31140047
-
项目类别:专项基金项目
-
资助金额:10.0万元
-
批准年份:2011
-
负责人:邹艺辉
-
依托单位:
骨形态发生蛋白(Bone Morphogenetic Proteins,BMP)信号在脊髓损伤中枢神经性疼痛中的作用
-
批准号:81070994
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:王亚平
-
依托单位: